Carrick Therapeutics is building an innovative portfolio of first-in-class oncology therapies that target the most aggressive and resistance forms of cancer, with research and development teams located in Dublin, Ireland, and Oxford, UK.
Carrick Therapeutics Chief Executive Dr. Elaine Sullivan, is a former Vice President for research and development functions at US pharmaceutical giant Eli Lilly and UK medical leader AstraZeneca.
Carrick Therapeutics is building an innovative portfolio of first-in-class oncology therapies that target the most aggressive and resistance forms of cancer, with research and development teams located in Dublin, Ireland, and Oxford, UK.
Carrick Therapeutics Chief Executive Dr. Elaine Sullivan, is a former Vice President for research and development functions at US pharmaceutical giant Eli Lilly and UK medical leader AstraZeneca.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/carrick-therapeutics” connections=”true” suffix=””]
Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that are advanced through understanding the mechanisms that cause cancer and resistance and tailored to an individual patients tumour.
Carrick Therapeutics has partnered with a network of clinicians and scientists, including Cancer Research UK, and researchers at Cambridge, Imperial College London, and Oxford.
In Oct 2016, Carrick Therapeutics raised $95Mn in a series A funding round led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Evotec AG, GV (Google Ventures), and Lightstone Ventures.
Recover your password.
A password will be e-mailed to you.